# A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

> **NCT05931380** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 238 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05931380
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-31
- **Primary completion:** 2025-06-19
- **Final completion:** 2025-06-19
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931380, "A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05931380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*